Official Title

Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) and COVID Pandemic-related Stress

Purpose

The purpose of this study is to better understand how Mindfulness-based Mind-Body therapies work to help people with Posttraumatic Stress and Stress and Anxiety related to the COVID Pandemic. We want to learn more about how these treatments work so we can put together better treatments for people with PTSD and stress or worry. Time in the study altogether is generally about 16-18 weeks

Could this study be right for you?

For those suffering from PTSD: - Must be between 18 – 72 years of age - Must have current clinically significant symptoms of PTSD - Must be able to come to OSU Columbus campus for fMRI brain scan - Must be appropriate for group therapy Eligibility for those with Pandemic Stress: - Must be between 18 – 72 years of age - Must have current stress related to the pandemic - Must reside in selected zip codes / under-resourced areas in central Ohio (areas with high levels of residents with incomes near the poverty line) - Must be able to come to OSU Columbus campus for fMRI brain scan - Must be appropriate for group therapy - May have up to moderate depression and/or anxiety

Age Range

18 and up

Official Title

Trauma and Neurobiological Threat Reactivity as Risk Factors for Alcohol Abuse in Youth

Purpose

This research study will look at how brain and behavioral responses to emotional prompts relate to future behaviors. This research is being done to better understand risk factors and behavior change in adolescents. The total time that you will be involved in this study is 15 hours including 4 in-person visits and online follow-up forms every 3-months for 2 years.

Could this study be right for you?

Eligibility Criteria includes: - 16-19 years old - No history of alcohol use disorder - History of Interpersonal Trauma - Voluntarily consumed at least 1 prior alcoholic beverage (partial list of inclusion criteria) Exclusion Criteria - Currently pregnant (positive pregnancy test), or trying to become pregnant (women) - Lifetime history of any substance use disorder (partial list of exclusion criteria)

Age Range

16 and up

Official Title

A5383, Randomized, Controlled Trial to Evaluate the Antiinflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT)

Purpose

The purpose of this study is to evaluate whether letermovir (Prevymis), taken as two 240 mg tablets (480 mg total) or one 480 mg tablet once daily for 48 weeks, reduces inflammation in adults with human immunodeficiency virus (HIV-1) who also have cytomegalovirus (CMV) without any symptoms and who have been on effective anti-HIV medication for at least one year. Reducing inflammation might in turn help prevent some longer-term consequences of HIV, like heart disease and diabetes. This study will also look at whether you experience any side effects to the study drug. The study will last for about 1 year and 2 months (about 11 months on either letermovir or no anti-CMV study reatment and then about another 3 months of follow-up).

Could this study be right for you?

• HIV and CMV antibody positive •greater than or equal to 40 years of age • Not currently using any of the following ART medications: efavirenz, nevirapine, etravirine, lopinavir/ritonavir, or once a day dosing of raltegravir (twice daily OK) • Not pregnant or breastfeeding or planning to become pregnant during the study • No use of anti-CMV drugs within 90 days prior to study participation • No active HCV or HBV in past 24 weeks No presence or history of atrial or ventricular tachycardias • All gender identities are eligible, but there are enrollment targets for cis-women or transgender women on gender-affirming hormones

Age Range

40 and up

Official Title

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in people with Depression

Purpose

The purpose of this study is to see if a new drug (BI 1358894), taken in addition to a current antidepressant, is useful and safe for treating patients with Major Depressive Disorder.

You will be in this study approximately 13 weeks and have about 8 visits to the study center. You will also have about 2 visits that will be done by phone.

Could this study be right for you?

Inclusion criteria:
- Between the ages of 18 and 65
- Currently taking an antidepressant
- Currently experiencing symptoms of depression

Age Range

18 and up

Official Title

A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV InfectionA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, for HIV Pre-Exposure to Those Having Sex with Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection

Purpose

The purpose of this study is to see if Lenacapavir is safe and effective to use as a pre-exposure prevention in Cisgender Men (CGM), Transgender Women (TGW), Transgender Men (TGM) and Gender Non-binary people (GNB), with a high risk of HIV infection.

Could this study be right for you?

• CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection. • HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months • Sexually active with ≥ 1 partner assigned male at birth in the last 12 months and 1 of the following: o Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks o History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks o Use of stimulants with sex in the last 12 weeks

Age Range

18 and up

Official Title

KNEE CREATIONS SCP® OBSERVATIONAL COHORT FOLLOW-UP STUDY

Purpose

A study for those who will (have undergone) the Subchondroplasty (SCP) procedure for their knee. SCP is a procedure performed on subjects who have bone marrow lesions(BMLs). BMLs are subchondral defects in the bone, also called Insufficiency Fractures. This follow-up study will collect information on the short- and long-term safety and effectiveness of the SCP procedure.

Could this study be right for you?

- 18 years of age or older
- Considered to be a candidate for SCP procedure by your surgeon
- Have agreed to undergo the SCP procedure or has already undergone the procedure
- Willing and able to sign a written consent form
- Has the ability and the willingness to contribute follow-up outcome data

Age Range

18 and up

Official Title

Determining the Optimal Treatment Intensity for Children with Language Impairment

Purpose

The purpose of the study is to determine the amount of speech-language intervention children need to make improvements.

We hope to identify the appropriate amount of intervention needed as well as the point at which adding more intervention is no longer beneficial.

Participation in this study will last for approximately 10 weeks with one 2 hour session before the book reading intervention, one 2 hour session after the book reading intervention and a 6-month follow up.

Could this study be right for you?

Inclusion Criteria:

• Your child is between the ages of 5 and 6 years 11 months old
• Has received a primary diagnosis of a Language Impairment with vocabulary deficits
• Receives Speech and Language services through their school
• Primarily communicates in English

Age Range

5 and up

Official Title

Healthy New Albany: Breast Cancer Project

Purpose

Determine the feasibility of delivering a community-based, lifestyle weight management intervention in producing meaningful improvements in weight loss and relevant clinical and patient-reported outcomes in Breast Cancer survivors.

Could this study be right for you?

Female breast cancer survivor within 60 months after cessation of active treatment. Overweight/Obese (BMI > 25). Ability to understand and willing to sign a written informed consent. Willing and physically able to participate in physical activity. Obtain physician consent via primary care physician and/or treating oncologist.

Age Range

30 and up

Official Title

Hepatitis C Virus Immunity in Women and Children

Purpose

This is a study to find out how pregnancy affects a mother’s immune system. (The “immune system” is the part of the body that fights germs.) This study is also to find out why some babies who are exposed to infections during pregnancy get infected and others do not.

To do this project we need to study some women and babies who are infected with the hepatitis C virus and others who are not. This will allow us to compare their immune systems.

Could this study be right for you?

You may be eligible to participate if you are:

PREGNANCY COHORT eligibility criteria:
1) Pregnant (enrollment preferably during 1st or 2nd trimester, but may occur as late as the delivery hospitalization)
2) HCV-RNA positive (#150) or HCV-RNA negative (#50)
3) Willing and able to attend all study visits

Exclusion criteria for mothers:
1) Inability to provide informed consent
2) Incarceration

Inclusion criteria for infants:
1) Child born to study mother

Exclusion criteria for infants:
1) In custody of county children’s services (Enrolled infants who are temporarily in custody of children’s services will not have further study blood draws, but lab results from blood tests ordered by their pediatrician may be followed to monitor the outcome of their HCV exposure. Infants who are later placed back in the custody of their mother or relative may be re-enrolled.)

NON-PREGNANCY COHORT eligibility criteria:
1) Willing and able to attend all study visits

Exclusion criteria:
1) Currently pregnant
2) Inability to provide informed consent
3) Incarceration

Official Title

Immune Response in Adolescents

Purpose

Our goal in this study is to learn more about the immune system in adolescence and early adulthood. We are looking to enroll healthy children ages 12-18 years old.

Enrollment in the study will require 1 visit to Nationwide Children’s Hospital involving a blood draw and 2 nasal swabs.
The visit will take approximately 1- 1 ½ hour(s). We ask that the family brings a copy of the child’s immunization record to the visit.

Could this study be right for you?

Children will need to meet the following criteria to be in the study:

Inclusion Criteria:
· Parents/Legal guardian able and willing to sign informed consent and the child is willing to sign assent form for participation. All forms are in English.
· Healthy children, age 12-18 years old

Exclusion Criteria:
· Any chronic or congenital conditions that may potentially affect immune responses
· Cough, congestion, fever, rhinorrhea, rash and any other symptoms indicative of infection within the 2 weeks prior to enrollment sampling
· HIV, AIDS or other immunodeficiencies or any other condition that may affect their immune system
· Use of systemic steroids within 2 weeks prior to enrollment
· Immunization(s) within the last 30 days

Age Range

12 and up

Official Title

ImproviNg The BrEast CaNcer Care DelivEry MoDel for Sex and Gender Minority Survivors (INTENDED for SGM)

Purpose

The long-term goal of this study is to improve decision quality and health-related outcomes for sexual gender minority (SGM) breast/chest cancer survivors. The goal is to evaluate important ways the current care model needs adjusted for SGM people, and how best to combine a socially important care model into clinical practice.

Survivors: Eligible participants will participate in a 90-minute focus group and online survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

Clinicians: Eligible participants will participate in a 30-minute interview and brief survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

Participation in this study will take no more than 1 hour and 30 minutes.

Could this study be right for you?

Survivors:

1. Self-identify as a member of the SGM community

2. Age ≥18 years at the time of signing the informed consent form

3. Breast/chest cancer survivor in active treatment or completed active treatment in the last 10 years (not including hormone therapy)

4. Be able to read and speak English

5. Have received care in the U.S.

6. Be able to participate in virtual meetings

 

Clinicians:

1. Physicians, advance practice providers, nurses, psychologists, social workers, therapists, technologists, and other trained clinical professionals

2. Provide care to individuals diagnosed with breast cancer in the U.S.

3. Be able to read and speak English

4. Be able to participate in virtual meetings

Age Range

18 and up

Official Title

A Hybrid Effectiveness-Implementation Trial to Improve Safe Driving among Teen Drivers with Traffic Violations

Purpose

The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent training, on parent-teen communications as well as teens' risky driving behaviors, unsafe driving behaviors, and subsequent traffic violations.

Could this study be right for you?

In order to be eligible:
- You must be 16 -18 years of age
- Need a valid State of Ohio driver's license (no learner's permit)
- Proof of car insurance
- Must drive more than one hour per week

Age Range

16 and up